Catalent

CDMO Catalent’s UpTempo℠ adeno-associated viral (AAV) platform process accelerates time from gene to clinic.

Catalent provides fill/finish services in a range of formats to support clinical and commercial products.

Shorten clinical development timeline using novel GPEx® Lightning technology

Catalent’s UpTempo Virtuoso™ AAV platform accelerates development, delivering clinical material in 9 months.

OneBio® Suite is an integrated solution for biologics development that reduces timelines, risk and complexity.

Catalent provides fill/finish services across a range of product formats from clinical to commercial scale.

Interest in mRNA as a therapeutic modality has exploded since the approval of mRNA-based COVID-19 vaccines.

Perfusion technology is a tool to increase productivity that can be applied at different stages during upstream cell culture for biotherapeutics products. Perfusion allows removal of waste by-products and replenishment of fresh nutrients so that the cells are able to grow and reach higher cell densities and higher productivity. N-1 perfusion, the application of the perfusion technology in the step immediately before the production bioreactor, is a good option for processes that exhibit low productivity. Join Claudia Berdugo, Ph.D., Director of Process Development at Catalent Biologics, for a podcast where she discusses N-1 perfusion and how Catalent Biologics works toward process improvements for each client to enable them to move their pharmaceutical products forward with confidence.

Catalent’s GPEx® Lightning provides next-generation cell line engineering to accelerate development of biologic molecules.